Philip Green, PhD, has extensive experience commercialising drug delivery products, with a specific focus on combination injectable devices and IV/SC switching. From 2009 to 2018 at Merck, Dr Green was responsible for commercial device strategies around subcutaneous biosimilars and oncology products. Previously, he worked for BD, where he was responsible for advanced drug delivery partnerships, including microneedles and wearable injectors. Prior to this he held multiple drug delivery development roles with Zyma and L’Oreal.

Dr Green received his BSc in Chemistry from Bristol University (UK), his PhD in Pharmaceutical Chemistry from the Welsh School of Pharmacy, Cardiff (UK) and undertook his postdoctoral research at the University of California, San Francisco (US).